Top

Journal of Translational Medicine

Published in:

Open Access 01-12-2023 | Parkinson's Disease | Research

miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling

Authors: Songzhe He, Qiongqiong Wang, Liankuai Chen, Yusheng Jason He, Xiaofang Wang, Shaogang Qu

Published in: Journal of Translational Medicine | Issue 1/2023

Abstract

Background

The pathogenesis of Parkinson's disease (PD) has not been fully elucidated, and there are no effective disease-modifying drugs for the treatment of PD. Mesenchymal stem cells have been used to treat several diseases, but are not readily available.

Methods

Here, we used phenotypically uniform trophoblast stage-derived mesenchymal stem cells (T-MSCs) from embryonic stem cells, which are capable of stable production, and their exosomes (T-MSCs-Exo) to explore the molecular mechanisms involved in dopaminergic (DA) neuron protection in PD models using experimental assays (e.g., western blotting, immunofluorescence and immunohistochemistry staining).

Results

We assessed the levels of DA neuron injury and oxidative stress in MPTP-induced PD mice and MPP⁺-induced MN9D cells after treating them with T-MSCs or T-MSCs-Exo. Furthermore, T-MSCs-Exo miRNA sequencing analysis revealed that miR-100-5p-enriched T-MSCs-Exo directly targeted the 3′ UTR of NOX4, which could protect against the loss of DA neurons, maintain nigro-striatal system function, ameliorate motor deficits, and reduce oxidative stress via the Nox4-ROS-Nrf2 axis in PD models.

Conclusions

The study suggests that miR-100-5p-enriched T-MSCs-Exo may be a promising biological agent for the treatment of PD.

Graphical Abstract

Schematic summary of the mechanism underlying the neuroprotective actions of T-MSCs-Exo in PD. T-MSCs Exo may inhibit the expression level of the target gene NOX4 by delivering miR-100-5p, thereby reducing ROS production and alleviating oxidative stress via the Nox4-ROS-Nrf2 axis, thus improving DA neuron damage in PD.

Available only for authorised users

Cheng Q, Wang J, Li M, Fang J, Ding H, Meng J, et al. CircSV2b participates in oxidative stress regulation through miR-5107-5p-Foxk1-Akt1 axis in Parkinson’s disease. Redox Biol. 2022;56: 102430. https://doi.org/10.1016/j.redox.2022.102430.CrossRefPubMedCentralPubMed

Peng H, Li Y, Ji W, Zhao R, Lu Z, Shen J, et al. Intranasal administration of self-oriented nanocarriers based on therapeutic exosomes for synergistic treatment of Parkinson’s disease. ACS Nano. 2022;16(1):869–84. https://doi.org/10.1021/acsnano.1c08473.CrossRefPubMed

Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet (London, England). 2021;397(10291):2284–303. https://doi.org/10.1016/S0140-6736(21)00218-X.CrossRefPubMed

Tesco G, Lomoio S. Pathophysiology of neurodegenerative diseases: an interplay among axonal transport failure, oxidative stress, and inflammation? Semin Immunol. 2022;59:101628. https://doi.org/10.1016/j.smim.2022.101628.CrossRefPubMedCentralPubMed

Ma J, Shi X, Li M, Chen S, Gu Q, Zheng J, et al. MicroRNA-181a-2-3p shuttled by mesenchymal stem cell-secreted extracellular vesicles inhibits oxidative stress in Parkinson’s disease by inhibiting EGR1 and NOX4. Cell Death Discov. 2022;8(1):33. https://doi.org/10.1038/s41420-022-00823-x.CrossRefPubMedCentralPubMed

Dorsey ER, Bloem BR. The Parkinson pandemic-A call to action. JAMA Neurol. 2018;75(1):9–10. https://doi.org/10.1001/jamaneurol.2017.3299.CrossRefPubMed

Elkouzi A, Vedam-Mai V, Eisinger RS, Okun MS. Emerging therapies in Parkinson disease—repurposed drugs and new approaches. Nat Rev Neurol. 2019;15(4):204–23. https://doi.org/10.1038/s41582-019-0155-7.CrossRefPubMedCentralPubMed

Zhou T, Yuan Z, Weng J, Pei D, Du X, He C, et al. Challenges and advances in clinical applications of mesenchymal stromal cells. J Hematol Oncol. 2021;14(1):24. https://doi.org/10.1186/s13045-021-01037-x.CrossRefPubMedCentralPubMed

Wang LT, Liu KJ, Sytwu HK, Yen ML, Yen BL. Advances in mesenchymal stem cell therapy for immune and inflammatory diseases: use of cell-free products and human pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Transl Med. 2021;10(9):1288–303. https://doi.org/10.1002/sctm.21-0021.CrossRefPubMedCentralPubMed

10.

Andrzejewska A, Dabrowska S, Lukomska B, Janowski M. Mesenchymal stem cells for neurological disorders. Adv Sci (Weinh). 2021;8(7):2002944. https://doi.org/10.1002/advs.202002944.CrossRefPubMed

11.

Alizadeh R, Boroujeni ME, Kamrava SK, Tehrani AM, Bagher Z, Heidari F, et al. From transcriptome to behavior: intranasal injection of late passage human olfactory stem cells displays potential in a rat model of Parkinson’s disease. ACS Chem Neurosci. 2021;12(12):2209–17. https://doi.org/10.1021/acschemneuro.1c00225.CrossRefPubMed

12.

Sun Z, Gu P, Xu H, Zhao W, Zhou Y, Zhou L, et al. Human umbilical cord mesenchymal stem cells improve locomotor function in parkinson’s disease mouse model through regulating intestinal microorganisms. Front Cell Dev Biol. 2021;9: 808905. https://doi.org/10.3389/fcell.2021.808905.CrossRefPubMed

13.

Chen WS, Lin TY, Kuo CH, Hsieh DJ, Kuo WW, Liao SC, et al. Ginkgolide A improves the pleiotropic function and reinforces the neuroprotective effects by mesenchymal stem cell-derived exosomes in 6-OHDA-induced cell model of Parkinson’s disease. Aging. 2023;15(5):1358–70. https://doi.org/10.18632/aging.204526.CrossRefPubMedCentralPubMed

14.

Schiess M, Suescun J, Doursout MF, Adams C, Green C, Saltarrelli JG, et al. Allogeneic bone marrow-derived mesenchymal stem cell safety in idiopathic Parkinson’s disease. Mov Disord. 2021;36(8):1825–34. https://doi.org/10.1002/mds.28582.CrossRefPubMedCentralPubMed

15.

Wang X, Lazorchak AS, Song L, Li E, Zhang Z, Jiang B, et al. Immune modulatory mesenchymal stem cells derived from human embryonic stem cells through a trophoblast-like stage. Stem cells. 2016;34(2):380–91. https://doi.org/10.1002/stem.2242.CrossRefPubMed

16.

Wang X, Kimbrel EA, Ijichi K, Paul D, Lazorchak AS, Chu J, et al. Human ESC-derived MSCs outperform bone marrow MSCs in the treatment of an EAE model of multiple sclerosis. Stem cell reports. 2014;3(1):115–30. https://doi.org/10.1016/j.stemcr.2014.04.020.CrossRefPubMedCentralPubMed

17.

Pinnell JR, Cui M, Tieu K. Exosomes in Parkinson disease. J Neurochem. 2021;157(3):413–28. https://doi.org/10.1111/jnc.15288.CrossRefPubMedCentralPubMed

18.

Mo C, Zhao J, Liang J, Wang H, Chen Y, Huang G. Exosomes: a novel insight into traditional Chinese medicine. Front Pharmacol. 2022;13: 844782. https://doi.org/10.3389/fphar.2022.844782.CrossRefPubMedCentralPubMed

19.

Xu M, Feng T, Liu B, Qiu F, Xu Y, Zhao Y, et al. Engineered exosomes: desirable target-tracking characteristics for cerebrovascular and neurodegenerative disease therapies. Theranostics. 2021;11(18):8926–44. https://doi.org/10.7150/thno.62330.CrossRefPubMedCentralPubMed

20.

Shao H, Im H, Castro CM, Breakefield X, Weissleder R, Lee H. New technologies for analysis of extracellular vesicles. Chem Rev. 2018;118(4):1917–50. https://doi.org/10.1021/acs.chemrev.7b00534.CrossRefPubMedCentralPubMed

21.

Riazifar M, Mohammadi MR, Pone EJ, Yeri A, Lasser C, Segaliny AI, et al. Stem cell-derived exosomes as nanotherapeutics for autoimmune and neurodegenerative disorders. ACS Nano. 2019;13(6):6670–88. https://doi.org/10.1021/acsnano.9b01004.CrossRefPubMedCentralPubMed

22.

Khare D, Or R, Resnick I, Barkatz C, Almogi-Hazan O, Avni B. Mesenchymal stromal cell-derived exosomes affect mRNA expression and function of B-lymphocytes. Front Immunol. 2018;9:3053. https://doi.org/10.3389/fimmu.2018.03053.CrossRefPubMedCentralPubMed

23.

Li Q, Wang Z, Xing H, Wang Y, Guo Y. Exosomes derived from miR-188-3p-modified adipose-derived mesenchymal stem cells protect Parkinson’s disease. Mol Ther Nucleic Acids. 2021;23:1334–44. https://doi.org/10.1016/j.omtn.2021.01.022.CrossRefPubMedCentralPubMed

24.

Xue C, Li X, Ba L, Zhang M, Yang Y, Gao Y, et al. MSC-derived exosomes can enhance the angiogenesis of human brain mecs and show therapeutic potential in a mouse model of Parkinson’s disease. Aging Dis. 2021;12(5):1211–22. https://doi.org/10.14336/AD.2020.1221.CrossRefPubMedCentralPubMed

25.

Jiang Y, Liu J, Chen L, Jin Y, Zhang G, Lin Z, et al. Serum secreted miR-137-containing exosomes affects oxidative stress of neurons by regulating OXR1 in Parkinson’s disease. Brain Res. 2019;1722: 146331. https://doi.org/10.1016/j.brainres.2019.146331.CrossRefPubMed

26.

Wu X, Meng X, Tan F, Jiao Z, Zhang X, Tong H, et al. Regulatory mechanism of miR-543-3p on GLT-1 in a mouse model of Parkinson’s disease. ACS Chem Neurosci. 2019;10(3):1791–800. https://doi.org/10.1021/acschemneuro.8b00683.CrossRefPubMed

27.

Jiao Z, Wu Y, Qu S. Fenpropathrin induces degeneration of dopaminergic neurons via disruption of the mitochondrial quality control system. Cell Death Discov. 2020;6:78. https://doi.org/10.1038/s41420-020-00313-y.CrossRefPubMedCentralPubMed

28.

Rider MA, Hurwitz SN, Meckes DG Jr. ExtraPEG: a polyethylene glycol-based method for enrichment of extracellular vesicles. Sci Rep. 2016;6:23978. https://doi.org/10.1038/srep23978.CrossRefPubMedCentralPubMed

29.

Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–7. https://doi.org/10.1080/14653240600855905.CrossRefPubMed

30.

Li KL, Huang HY, Ren H, Yang XL. Role of exosomes in the pathogenesis of inflammation in Parkinson’s disease. Neural Regen Res. 2022;17(9):1898–906. https://doi.org/10.4103/1673-5374.335143.CrossRefPubMedCentralPubMed

31.

Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. https://doi.org/10.1126/science.aau6977.CrossRefPubMedCentralPubMed

32.

Zhong Z, Tian Y, Luo X, Zou J, Wu L, Tian J. Extracellular vesicles derived from human umbilical cord mesenchymal stem cells protect against DOX-induced heart failure through the miR-100-5p/NOX4 pathway. Front Bioeng Biotechnol. 2021;9: 703241. https://doi.org/10.3389/fbioe.2021.703241.CrossRefPubMedCentralPubMed

33.

Arab HH, Safar MM, Shahin NN. Targeting ROS-dependent AKT/GSK-3beta/NF-kappaB and DJ-1/Nrf2 pathways by dapagliflozin attenuates neuronal injury and motor dysfunction in rotenone-induced parkinson’s disease rat model. ACS Chem Neurosci. 2021;12(4):689–703. https://doi.org/10.1021/acschemneuro.0c00722.CrossRefPubMed

34.

Xian P, Hei Y, Wang R, Wang T, Yang J, Li J, et al. Mesenchymal stem cell-derived exosomes as a nanotherapeutic agent for amelioration of inflammation-induced astrocyte alterations in mice. Theranostics. 2019;9(20):5956–75. https://doi.org/10.7150/thno.33872.CrossRefPubMedCentralPubMed

35.

Guo F, Wang X, Liu X. Protective effects of irigenin against 1-methyl-4-phenylpyridinium-induced neurotoxicity through regulating the Keap1/Nrf2 pathway. Phytother Res. 2021;35(3):1585–96. https://doi.org/10.1002/ptr.6926.CrossRefPubMed

36.

Huang B, Liu J, Meng T, Li Y, He D, Ran X, et al. Polydatin prevents lipopolysaccharide (LPS)-induced parkinson’s disease via regulation of the AKT/GSK3β-Nrf2/NF-κB signaling axis. Front Immunol. 2018;9:2527. https://doi.org/10.3389/fimmu.2018.02527.CrossRefPubMedCentralPubMed

37.

Wang T, Jian Z, Baskys A, Yang J, Li J, Guo H, et al. MSC-derived exosomes protect against oxidative stress-induced skin injury via adaptive regulation of the NRF2 defense system. Biomaterials. 2020;257: 120264. https://doi.org/10.1016/j.biomaterials.2020.120264.CrossRefPubMed

38.

Ma MW, Wang J, Zhang Q, Wang R, Dhandapani KM, Vadlamudi RK, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol Neurodegener. 2017;12(1):7. https://doi.org/10.1186/s13024-017-0150-7.CrossRefPubMedCentralPubMed

39.

Vermot A, Petit-Hartlein I, Smith SME, Fieschi F. NADPH oxidases (NOX): an overview from discovery, molecular mechanisms to physiology and pathology. Antioxidants. 2021;10(6):890. https://doi.org/10.3390/antiox10060890.CrossRefPubMedCentralPubMed

40.

Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson’s disease. Lancet Neurol. 2021;20(5):385–97. https://doi.org/10.1016/S1474-4422(21)00030-2.CrossRefPubMedCentralPubMed

41.

Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–60. https://doi.org/10.1001/jama.2019.22360.CrossRefPubMed

42.

Jiang B, Yan L, Wang X, Li E, Murphy K, Vaccaro K, et al. Concise review: mesenchymal stem cells derived from human pluripotent cells, an unlimited and quality-controllable source for therapeutic applications. Stem cells. 2019;37(5):572–81. https://doi.org/10.1002/stem.2964.CrossRefPubMed

43.

Pachon-Pena G, Serena C, Ejarque M, Petriz J, Duran X, Oliva-Olivera W, et al. Obesity determines the immunophenotypic profile and functional characteristics of human mesenchymal stem cells from adipose tissue. Stem Cells Transl Med. 2016;5(4):464–75. https://doi.org/10.5966/sctm.2015-0161.CrossRefPubMedCentralPubMed

44.

Ge S, Jiang X, Paul D, Song L, Wang X, Pachter JS. Human ES-derived MSCs correct TNF-alpha-mediated alterations in a blood-brain barrier model. Fluids and barriers of the CNS. 2019;16(1):18. https://doi.org/10.1186/s12987-019-0138-5.CrossRefPubMedCentralPubMed

45.

Xu J, Wang X, Chen J, Chen S, Li Z, Liu H, et al. Embryonic stem cell-derived mesenchymal stem cells promote colon epithelial integrity and regeneration by elevating circulating IGF-1 in colitis mice. Theranostics. 2020;10(26):12204–22. https://doi.org/10.7150/thno.47683.CrossRefPubMedCentralPubMed

46.

Borkar R, Wang X, Zheng D, Miao Z, Zhang Z, Li E, et al. Human ESC-derived MSCs enhance fat engraftment by promoting adipocyte reaggregation, secreting CCL2 and mobilizing macrophages. Biomaterials. 2021;272: 120756. https://doi.org/10.1016/j.biomaterials.2021.120756.CrossRefPubMed

47.

Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, et al. Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1(-/-) mice. Nature. 2019;571(7766):565–9. https://doi.org/10.1038/s41586-019-1405-y.CrossRefPubMed

48.

Su T, Xiao Y, Xiao Y, Guo Q, Li C, Huang Y, et al. Bone marrow mesenchymal stem cells-derived exosomal MiR-29b-3p regulates aging-associated insulin resistance. ACS Nano. 2019;13(2):2450–62. https://doi.org/10.1021/acsnano.8b09375.CrossRefPubMed

49.

Taguchi YH, Wang H. Exploring MicroRNA biomarkers for Parkinson’s disease from mRNA expression profiles. Cells. 2018;7(12):245. https://doi.org/10.3390/cells7120245.CrossRefPubMedCentralPubMed

50.

Lv B, Zhang X, Yuan J, Chen Y, Ding H, Cao X, et al. Biomaterial-supported MSC transplantation enhances cell-cell communication for spinal cord injury. Stem Cell Res Ther. 2021;12(1):36. https://doi.org/10.1186/s13287-020-02090-y.CrossRefPubMedCentralPubMed

51.

Chen X, Zhang Y, Wang W, Liu Z, Meng J, Han Z. Mesenchymal stem cells modified with heme oxygenase-1 have enhanced paracrine function and attenuate lipopolysaccharide-induced inflammatory and oxidative damage in pulmonary microvascular endothelial cells. Cell Physiol Biochem. 2018;49(1):101–22. https://doi.org/10.1159/000492847.CrossRefPubMed

52.

Martin JR, Patil P, Yu F, Gupta MK, Duvall CL. Enhanced stem cell retention and antioxidative protection with injectable, ROS-degradable PEG hydrogels. Biomaterials. 2020;263: 120377. https://doi.org/10.1016/j.biomaterials.2020.120377.CrossRefPubMedCentralPubMed

53.

Piekarska K, Urban-Wojciuk Z, Kurkowiak M, Pelikant-Malecka I, Schumacher A, Sakowska J, et al. Mesenchymal stem cells transfer mitochondria to allogeneic Tregs in an HLA-dependent manner improving their immunosuppressive activity. Nat Commun. 2022;13(1):856. https://doi.org/10.1038/s41467-022-28338-0.CrossRefPubMedCentralPubMed

54.

Li X, Michaeloudes C, Zhang Y, Wiegman CH, Adcock IM, Lian Q, et al. Mesenchymal stem cells alleviate oxidative stress-induced mitochondrial dysfunction in the airways. J Allergy Clin Immunol. 2018;141(5):1634-45.e5. https://doi.org/10.1016/j.jaci.2017.08.017.CrossRefPubMed

55.

Kizilay Mancini O, Lora M, Cuillerier A, Shum-Tim D, Hamdy R, Burelle Y, et al. Mitochondrial oxidative stress reduces the immunopotency of mesenchymal stromal cells in adults with coronary artery disease. Circ Res. 2018;122(2):255–66. https://doi.org/10.1161/CIRCRESAHA.117.311400.CrossRefPubMed

56.

Boonpraman N, Yoon S, Kim CY, Moon JS, Yi SS. NOX4 as a critical effector mediating neuroinflammatory cytokines, myeloperoxidase and osteopontin, specifically in astrocytes in the hippocampus in Parkinson’s disease. Redox Biol. 2023;62: 102698. https://doi.org/10.1016/j.redox.2023.102698.CrossRefPubMedCentralPubMed

57.

Dawson VL, Dawson TM. Promising disease-modifying therapies for Parkinson’s disease. Sci Transl Med. 2019;11(520):eaba1659. https://doi.org/10.1126/scitranslmed.aba1659.CrossRefPubMed

Title: miR-100a-5p-enriched exosomes derived from mesenchymal stem cells enhance the anti-oxidant effect in a Parkinson’s disease model via regulation of Nox4/ROS/Nrf2 signaling
Authors: Songzhe He
Qiongqiong Wang
Liankuai Chen
Yusheng Jason He
Xiaofang Wang
Shaogang Qu
Publication date: 01-12-2023
Publisher: BioMed Central
Keyword: Parkinson's Disease
Published in: Journal of Translational Medicine / Issue 1/2023
Electronic ISSN: 1479-5876
DOI: https://doi.org/10.1186/s12967-023-04638-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Graphical Abstract

Please log in to get access to this content

Other articles of this Issue 1/2023

Rocuronium bromide suppresses esophageal cancer via blocking the secretion of C–X–C motif chemokine ligand 12 from cancer associated fibroblasts

Identifying a distinct fibrosis subset of NAFLD via molecular profiling and the involvement of profibrotic macrophages

Drug repositioning targeting glutaminase reveals drug candidates for the treatment of Alzheimer’s disease patients

Identification of the MMP family as therapeutic targets and prognostic biomarkers in the microenvironment of head and neck squamous cell carcinoma

Potential clinical implications of CD4+CD26high T cells for nivolumab treated melanoma patients

Glucose metabolic reprogramming and its therapeutic potential in obesity-associated endometrial cancer

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials